Document Detail

Frequent dose delays and growth factor requirements with the sequential doxorubicin-CMF schedule.
MedLine Citation:
PMID:  9490086     Owner:  NLM     Status:  MEDLINE    
Doxorubicin for four cycles plus cyclophosphamide, methotrexate and 5-fluorouracil (CMF) for eight cycles is an effective adjuvant regimen for breast cancer patients with more than three involved axillary lymph nodes. We reviewed the incidence of dose delays and growth factor requirements when this regimen is administered to patients receiving concurrent irradiation. Thirty-six patients with more than three involved axillary lymph nodes were treated with the sequential regimen doxorubicin-CMF and irradiation. Patients with two or more dose delays received G-CSF treatment. Seventy-five percent of the patients required dose delays for day-22 neutropenia, and growth factors were needed for half of the patients in order to maintain a received dose intensity of 0.940. The first delayed cycle occurred in 74% of the patients while receiving concomitant chemoradiotherapy. Frequent dose delays were required when the sequential regimen doxorubicin-CMF was administered along with radiotherapy. Growth factors are needed to maintain dose intensity similar to that achieved in the original trial.
A Ribas; J Albanell; J Bellmunt; B Bermejo; E Gallardo; R Vera; R Bodi; L A Solé-Calvo
Related Documents :
25055166 - Efficacy of anti-fungal but not anti-bacterial prophylaxis in intensive primary aml the...
9490086 - Frequent dose delays and growth factor requirements with the sequential doxorubicin-cmf...
11919236 - Prognostic significance of the number of axillary lymph nodes removed in patients with ...
9196016 - Computer-derived nuclear features compared with axillary lymph node status for breast c...
19656566 - Incorporating novel agents in the treatment of myelodysplastic syndromes.
8522446 - Elevated carcinoembryonic antigen levels correlating with disease recurrence in a patie...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Acta oncologica (Stockholm, Sweden)     Volume:  36     ISSN:  0284-186X     ISO Abbreviation:  Acta Oncol     Publication Date:  1997  
Date Detail:
Created Date:  1998-03-05     Completed Date:  1998-03-05     Revised Date:  2009-05-12    
Medline Journal Info:
Nlm Unique ID:  8709065     Medline TA:  Acta Oncol     Country:  NORWAY    
Other Details:
Languages:  eng     Pagination:  701-4     Citation Subset:  IM    
Medical Oncology Service, Hospital General Universitari Vall d'Hebron, Barcelona, Spain.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antibiotics, Antineoplastic / administration & dosage
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
Breast Neoplasms / drug therapy*,  radiotherapy
Chemotherapy, Adjuvant
Cyclophosphamide / administration & dosage
Doxorubicin / administration & dosage
Fluorouracil / administration & dosage
Granulocyte Colony-Stimulating Factor / administration & dosage,  therapeutic use
Growth Substances / therapeutic use*
Methotrexate / administration & dosage
Middle Aged
Reg. No./Substance:
0/Antibiotics, Antineoplastic; 0/CMF regimen; 0/Growth Substances; 143011-72-7/Granulocyte Colony-Stimulating Factor; 23214-92-8/Doxorubicin; 50-18-0/Cyclophosphamide; 51-21-8/Fluorouracil; 59-05-2/Methotrexate

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Expression of fibroblast growth factor 2 mRNA in early and advanced gastric cancer.
Next Document:  Effects of fractionated abdominal irradiation on small intestinal motility--studies in a novel in vi...